NC18 / Novacyte Therap, Fosun Pharma - LARVOL DELTA

Superior anti-tumor activity of NC18, a novel HER2-targeting ADC, against enhertu-resistant CDX model (ESMO Asia 2024) - "NC030-107 is currently undergoing preclinical evaluation. Conclusions In summary, FDA and CDE have approved NC18 for clinical trials in HER2-positive/expressing advanced solid tumors, and the findings in this paper strongly support an expanded patient population with Enhertu resistance."

Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • ALDH3A1 • HER-2 • UGT1A6